2.1. Study Design and Participants
obesity
OBESITY, TYPE 2 DIABETES
This study was a proof-of-concept, active drug-controlled, randomized controlled trial (RCT) performed at the Seoul National University Bundang Hospital (SNUBH, Seongnam, Republic of Korea) from 2017 to 2021. Individuals with type 2 diabetes and obesity were eligible if they were aged ≥20 years, had not received any antidiabetic agents during the previous 6 weeks, and had a body mass index (BMI) ≥25 kg/mA total of 70 participants were assigned randomly (1:1) to either gemigliptin 50 mg with metformin 1000 mg/day (gemigliptin–metformin group) or glimepiride 2 mg with metformin 1000 mg/day (glimepiride–metformin group; 